Improving Fibrosis Outcomes With Metformin

Phase 2

Withdrawn

• Conditions: Hepatitis C; HIV Infection
• Interventions: Drug: No metformin treatment; Drug: Metformin

• Registration Number: NCT02306070
• Lead Sponsor: Ottawa Hospital Research Institute

Brief Summary

This study will evaluate the role of Metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance receiving DAA HCV treatment.

Detailed Description

HCV antiviral therapy has evolved rapidly in recent years and access to these medications has improved. While SVR is associated with improved liver outcomes, the rate of liver fibrosis regression with SVR is variable and predictors of regression are not well established. In addition, achieving SVR in patients with cirrhosis does not necessarily prevent decompensation or eliminate the risk of HCC. A better understanding of the role insulin resistance and impaired glucose metabolism have on these outcomes in HCV patients who achieve SVR are needed.

Identifying and targeting potentially modifiable risk factors such as IR may be of significant importance in preventing progression of and promoting regression of liver fibrosis, reducing mortality and improving outcomes for HCV-HIV co-infected and HCV-mono-infected patients.

This proposed pilot study will be the first to evaluate the role of Metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with IR receiving DAA HCV treatment.

If Metformin is effective in reducing liver fibrosis in this patient population, this will represent a well-tolerated, easy to administer, inexpensive therapy that will protect against negative HCV outcomes. This study will also be an opportunity to evaluate the impact of insulin resistance and hyperglycemia have on viral clearance HCV-infected patients treated with interferon-free regimens. In addition, the study will further explore the relationship between HCV, insulin resistance and AFP levels.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2014-11-02
• Study First Submitted QC: 2014-11-28
• Study First Posted: 2014-12-03
• Study Start: 2016-01
• Status Verified: 2017-09
• Primary Completion: 2017-09-30
• Study Completion: 2018-04-03
• Last Update Submitted: 2018-04-13
• Last Update Posted: 2018-04-17

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Male or female, 18 to 79 years old inclusive
2. Provision of informed consent
3. Documented history of chronic HCV RNA infection
4. Intending to start on any 8-12 week IFN-free HCV antiviral therapy
5. If HIV-infected and not on HIV antiretroviral therapy, a CD4 count at least > 200
6. Insulin resistance as determined by a HOMA-IR of > 2.0 at screening
7. Evidence of fibrosis on FibroScan® > 8.0 kPa, OR liver biopsy score > 2 (Batts-Ludwig System) [55] (within 2 years)

Read More

Exclusion Criteria

1. Pregnant, suspected to be pregnant, planning to become pregnant or breastfeeding
2. Chronic HBV infection
3. HbA1c > 8.0
4. Use of immune suppressing medications
5. Active malignancy
6. Current or any previous treatment with Metformin, other oral diabetes medications,insulin
7. Pre-existing diabetes (type 1, type 2 or gestational diabetes)
8. Clinical evidence of decompensated cirrhosis (ascites, esophageal varices, hepatic encephalopathy, hepatocellular carcinoma)
9. Presence of renal impairment or when renal function is not known, and also in patients with serum creatinine levels above upper limit of normal range. Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels >= 136 umol/L (males), >= 124 umol/L (females) or abnormal creatinine clearance (60 mL/min))
10. History of congestive heart failure requiring pharmacologic therapy
11. Wilson's disease
12. Alpha-1 antitrypsin
13. Hemochromatosis
14. Biliary Cirrhosis
15. Alcohol consumption > 50 g / day on average (see Appendix B for conversion to volume)
16. Participation in other clinical investigations during the study
17. History of lactic acidosis, irrespective of precipitating factors

Active illicit drug use and stable health illness will not be exclusionary assuming it is unlikely to compromise study adherence to protocol and study drug. In HIV-infected participants, HIV antiretroviral use and suppressed HIV viral load will not be required for participation.

HCV antiviral therapy will not be withheld for any participant that is eligible and desires to start treatment. If HCV treatment is anticipated to be started during the 48-week period of assessment, then participants will not be enrolled.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
No Metformin + Lifestyle modification	No metformin treatment	No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
Metformin + lifestyle modification	Metformin	Metformin + lifestyle modification pre, during and post HCV antiviral therapy

Primary Outcome Measures

Name	Time	Method
Change in FibroScan® score (kPa) from baseline to week 12 (start of HCV treatment), compared between treatment groups.	12 weeks	liver elastography score (kPa)

Secondary Outcome Measures

Name	Time	Method
Participant acceptability to study medication dosing (in Arm 1 only)	8, 24, 48 weeks	Participant acceptability will be evaluated in Arm 1 only using the Treatment Satisfaction Questionnaire for Medication (TSQM), Version 1.4
Virological response rates (SVR 12 weeks post HCV antiviral therapy) between treatment groups.	12 weeks	HCV RNA level (IU/mL)
Change in APRI measurements from baseline compared between treatment groups.	12, 24, 48weeks	calculated APRI
Change from baseline in glucose metabolism (HOMA-IR, fasting insulin, glucose levels)	4, 8, 12, 24, 36, 48 weeks	fasting glucose and insulin
Changes from baseline in lipid levels	12, 36, 48 weeks	fasting total cholesterol, LDL-c, HDL-c, triglycerides
Changes from baseline in anthropometric measures	4, 8, 12, 24, 36, 48 weeks	waist circumference, body weight and BMI
Changes from baseline in liver-related inflammatory markers	4, 8, 12, 24, 36 weeks	IL-6, IL-8, TNF-alpha, TGF-beta, C-reactive protein
Changes in AFP levels from baseline	12, 24, 36, 48 weeks	AFP
Changes from baseline in diet	24, 48 weeks	Changes in diet from baseline will be captured using the International Physical Activity Questionnaire short-form (IPAQ-sf)
Changes from baseline in physical exercise parameters	24, 48 weeks	Changes in physical activity from baseline will be captured using the International Physical Activity Questionnaire short-form (IPAQ-sf)

Trial Locations

Locations (1)

The Ottawa Hospital, General Campus; 🇨🇦 Ottawa, Ontario, Canada